Lugo

• SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS Ended
  2024-519633-35-00 6 2021-10-25 Resectable pancreatic adenocarcinoma with risk factors
• A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr … Ended
  2024-514611-98-00 5 2021-07-20 PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previousl
• Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung c … Ended
  2024-514803-33-00 4 2021-06-16 Non-small cell lung cancer (NSCLC)
• A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab … Ended
  2023-507317-10-00 5 2021-05-10 Locally advanced, unresectable, or metastatic non small cell lung canc
• A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small C … Ended
  2024-516598-60-00 5 2020-12-18 Advanced Non-Squamous Non-Small Cell Lung Cancer
• A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and C … Ended
  2022-502031-20-00 10 2020-12-17 Non-squamous non-small cell lung cancer (NSCLC)
• TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended
  2023-505894-33-00 4 2020-11-25 Lung Cancer, Non-Small Cell
• Clinical trial to assess the efficacy and safety of a vaccine for dust mite allergy Ended
  2024-514090-21-00 5 2020-08-05 Aetiological treatment of moderate - severe intermittent or persistent
• First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended
  2022-502124-52-00 5 2018-12-18 Advanced epithelial ovarian cancer
• A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in … Ended
  2024-512158-12-00 5 2018-12-14 Bladder Cancer Muscle-Invasive Bladder Cancer
• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 5 2018-10-15 Focal segmental glomerulosclerosis (FSGS)
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer
• A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Urothelial Cancer Ended
  2023-510296-56-00 5 2018-03-26 Advanced Urothelial Cancer
• Normal saline versus lactated Ringer’s solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: … Ended
  2023-509879-16-00 6 Acute pancreatitis
• Simvastatin in the Prevention of Recurrent Pancreatitis, a Triple Blind, Randomized Controlled Trial. Ended
  2024-513188-17-03 6 Recurrent pancreatitis
• A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nons … Ended
  2024-515393-27-00 4 Nonsquamous non-small cell lung cancer

Showing 121–136 of 136 trials